Blood-brain barrier permeable anticholinesterase aurones: Synthesis, structure-activity relationship, and drug-like properties

European Journal of Medicinal Chemistry

Volumn 94, Issue , 2015, Pages 195-210

  Liew, Kok Fui ^a   Chan, Kit Lam ^a   Lee, Chong Yew ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

Acetylcholinesterase inhibitors; Aurones; Bloodebrain barrier permeability; Drug like properties; Metabolic stability; Structureeactivity relationship

Indexed keywords

2 (4 HYDOXYBENZYLIDENE) 6 METHOXYBENZOFURAN 3(2H) ONE; 2',4' IHYDROXY 2 BROMOACETOPHENONE; 4 HYDROXYBENZALDEHYDE; 6 HYDROXY 2 (3,4,5 TRIMETHOXY BENZYLIDENE) BENZOFURAN 3 ONE; 6 HYDROXY 2 (4 METHOXY BENZYLIDENE) BENZOFURAN 3 ONE; 6 HYDROXYBENZOFURAN 3(2H) ONE; 6 METHOXY 2 PYRIDIN 4 YLMETHYLENE BENZOFURAN 3(2H) ONE; 6 METHOXYBENZOFURAN 3(2H) ONE; ACETYLCHOLINESTERASE; AURONE DERIVATIVE; CHOLINESTERASE INHIBITOR; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; AURONE; BENZOFURAN DERIVATIVE;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; DRUG SYNTHESIS; IC50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; MEMBRANE PERMEABILITY; MOLECULAR DOCKING; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION; TORPEDO CALIFORNICA; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; ENZYME ACTIVE SITE; METABOLISM; PERMEABILITY; PRECLINICAL STUDY; PROCEDURES; SYNTHESIS; TORPEDO;

ACETYLCHOLINESTERASE; ANIMALS; BENZOFURANS; BLOOD-BRAIN BARRIER; CATALYTIC DOMAIN; CHEMISTRY TECHNIQUES, SYNTHETIC; CHOLINESTERASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; MICROSOMES, LIVER; MOLECULAR DOCKING SIMULATION; PERMEABILITY; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TORPEDO;

EID: 84924366483     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.02.055     Document Type: Article

References (49)

1. A.V. Terry, J.J. Buccafusco, The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development, J. Pharmacol. Exp. Ther. 306 (2003) 821-827.
2. L.A. Craig, N.S. Hong, R.J. McDonald, Revisiting the cholinergic hypothesis in the development of Alzheimer's disease, Neurosci. Biobehav. Rev. 35 (2011) 1397-1409.
3. S. Salomone, F. Caraci, G.M. Leggio, J. Fedotova, F. Drago, New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs, Br. J. Clin. Pharmacol. 73 (2012) 504-517.
4. D. Galimberti, E. Scarpini, Disease-modifying treatments for Alzheimer's disease, Ther. Adv. Neurol. Disord. 4 (2011) 203-216.
5. M. Citron, Alzheimer's disease: strategies for disease modification, Nat. Rev. Drug Discov. 9 (2010) 387-398.
6. H.Y. Zhang, One-compound-multiple-targets strategy to combat Alzheimer's disease, FEBS Lett. 579 (2005) 5260-5264.
7. M. Rosini, V. Andrisano, M. Bartolini, M.L. Bolognesi, P. Hrelia, A. Minarini, A. Tarozzi, C. Melchiorre, Rational approach to discover multipotent anti-Alzheimer drugs, J. Med. Chem. 48 (2005) 360-363.
8. E. Nepovimova, E. Uliassi, J. Korabecny, L.E. Peña-Altamira, S. Samez, A. Pesaresi, G.E. Garcia, M. Bartolini, V. Andrisano, et al., Multitarget drug design strategy: QuinoneeTacrine hybrids designed to block amyloid-b aggregation and to exert anticholinesterase and antioxidant effects, J. Med. Chem. 57 (2014) 8576-8589.
9. M. Bajda, N. Guzior, M. Ignasik, B. Malawska, Multi-target-directed ligands in Alzheimer's disease treatment, Curr. Med. Chem. 18 (2011) 4949-4975.
10. T. Sato, T. Nakayama, S. Kikuchi, Y. Fukui, K. Yonekura-Sakakibara, T. Ueda, T. Nishino, Y. Tanaka, T. Kusumi, Enzymatic formation of aurones in the extracts of yellow snapdragon flowers, Plant Sci. 160 (2001) 229-236.
11. R. Haudecoeur, A. Ahamed-Belcem, Y. Wei, A. Fortuné, R. Brillet, C. Belle, E. Nicolle, C. Pallier, J.-M. Pawlotsky, A. Boumendjel, Discovery of naturally occurring aurones that are potent allosteric inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, J. Med. Chem. 54 (2011) 5395-5402.
12. C.Y. Lee, E.H. Chew, M.L. Go, Functionalized aurones as inducers of NAD(P)H: quinone oxidoreductase1 that activate AhR/XRE and Nrf2/ARE signaling pathways: synthesis, evaluation and SAR, Euro. J. Med. Chem. 45 (2010) 2957-2971.
13. H.M. Sim, K.Y. Loh, W.K. Yeo, C.Y. Lee, M.L. Go, Aurones as modulators of ABCG2 and ABCB1: synthesis and structure-activity relationships, Chem-Med Chem 6 (2011) 713-724.
14. H. Nadri, M. Pirali-Hamedani, M. Shekarchi, M. Abdollahi, V. Sheibani, M. Amanlou, A. Shafiee, A. Foroumadi, Design, synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran- 2(3H)-ylidene) methyl) pyridinium derivatives, Bioorg. Med. Chem. 18 (2010) 6360-6366.
15. 2 productions in LPS-induced RAW 264.7 cells, Bioorg. Med. Chem. Lett. 21 (2011) 4520-4523.
16. Y. Maya, M. Ono, H. Watanabe, M. Haratake, H. Saiji, M. Nkayama, Novel radioiodinated aurones as probes for Permeability of controls in the PAMPABBB assay imaging of beta-amyloid plaques in the brain, Bioconjugate Chem. 20 (2009) 95-101.
17. Molecular Weight and Topological Polar Surface Area of 2-benzylidenebenzofuran-3(2H)-ones were Obtained using Chem Bio Draw Ultra 13.0 (CambridgeSoft).
18. L. Di, E.H. Kerns, Profiling drug-like properties in discovery research, Curr. Opin. Chem. Biol. 7 (2003) 402-408.
19. E.H. Kerns, L. Di, Blood-brain barrier, in: Drug-like Properties: Concepts, Structure Design and Methods, Academic Press, London, p, 2008, pp. 122-136.
20. K.A. Youdim, M.Z. Qaiser, D.J. Bagley, C.C. Rice-Evans, N.J. Abbott, Flavonoid permeability across an in situ model of the bloodebrain barrier, Free Rad. Biol. Med. 36 (2003) 592-604.
21. A. Faria, D. Pestana, D. Teixeira, J. Azevedo, V. De Freitas, N. Mateus, C. Calhau, Flavonoid transport across RBE4 cells: a blood-brain barrier model, Cell. Mol. Biol. Lett. 15 (2010) 234-241.
22. W.A. Banks, Characteristics of compounds that cross the blood-brain barrier, BMC Neurol. 9 (Suppl. 1) (2009) S3.
23. W.M. Pardridge, Drug transport across the blood-brian barrier, J. Cereb. Blood Flow Metab. 32 (2012) 1959-1972.
24. J.-W. Yan, Y.-P. Li, W.-J. Ye, S.-B. Chen, J.-Q. Hou, J.-H. Tan, T.-M. Ou, D. Li, L.- Q. Gu, Z.-S. Huang, Design, synthesis and evaluation of isaindigotone derivatives as dual inhibitors for acetylcholinesterase and amyloid beta aggregation, Bioorg Med. Chem. 20 (2012) 2529-2534.
25. L.-F. Pan, X.-B. Wang, S.-S. Xie, S.-Y. Li, L.-Y. Kong, Multitarget-directed resveratrol derivatives: anti-cholinesterases, anti-b-amyloid aggregation and monoamine oxidase inhibition properties against Alzheimer's disease, Med-Chem Comm 5 (2014) 609-616.
26. A. Rampa, L. Piazzi, F. Belluti, S. Gobbi, A. Bisi, M. Bartolini, V. Andrisano, V. Cavrini, A. Cavalli, M. Recanatini, P. Valenti, Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl) methyl]aminoalkoxyaryl derivatives, J. Med. Chem. 44 (2001) 3810-3820.
27. F. Belluti, A. Rampa, L. Piazzi, A. Bisi, S. Gobbi, M. Bartolini, V. Andrisano, A. Cavalli, M. Recanatini, P. Valenti, Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation, J. Med. Chem. 48 (2005) 4444-4456.
28. S. Okombi, D. Rival, S. Bonnet, A.M. Mariotte, E. Perrier, A. Boumendjel, Discovery of benzylidenebenzofuran-3(2H)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes, J. Med. Chem. 49 (2006) 329-333.
29. H. Sugimoto, Y. Iimura, Y. Yamnishi, K. Yamatsu, Synthesis and structureactivity relationships of acetylcholinesterase inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds, J. Med. Chem. 38 (1995) 4821-4829
30. Y.K. Yeung, M.A. Ali, C.W. Ang, S.C. Tan, K.-Y. Khaw, M. Vikneswaran, O. Hasnah, Synthesis, characterization, and molecular docking of novel benzimidazole derivatives as cholinesterase inhibitors, Bioorg. Chem. 49 (2013) 33-39.
31. F.-C. Meng, F. Mao, W.-J. Shan, F. Qin, L. Huang, X.-S. Li, Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents, Bioorg. Med. Chem. Lett. 22 (2012) 4462-4466.
32. G. Kryger, I. Silman, J.L. Sussman, Structure of acetylcholinesterase complexed with E2020 (Aricept®): implications for the design of new anti-Alzheimer drugs, Structure 7 (1999) 297-307.
33. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, A.J. Olson, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, J. Comput. Chem. 19 (1998) 1639-1662.
34. Y.N. Imai, Y. Inoue, I. Nakanishi, K. Kitaura, Cl-p interactions in protein-ligand complexes, Protein Sci. 17 (2008) 1129-1137.
35. H. Matter, M. Nazaré, S. Güssregen, D.W. Will, H. Scheuder, A. Bauer, M. Urmann, K. Ritter, M. Wagner, V. Wehner, Evidence for C-Cl/C-Br⋯pi interactions as an important contribution to protein-ligand binding affinity, Angew. Chem. Int. Ed. Engl. 48 (2009) 2911-2916.
36. M.R. Scholfield, C.M. Zanden, M. Carter, P.S. Ho, Halogen bonding (X-bonding): a biological perspective, Protein Sci. 22 (2013) 139-152.
37. Y. Lu, T. Shi, Y. Wang, H. Yang, X. Yan, X. Luo, H. Jiang, W. Zhu, Halogen bonding - a novel interaction for rational drug design? J. Med. Chem. 52 (2009) 2852-2862.
38. Y. Lu, Y. Wang, W. Zhu, Nonbonding interactions of organic halogens in biological systems: implications for drug discovery and biomolecular design, Phys. Chem. Chem. Phys. 12 (2010) 4543-4551.
39. M. Nazare, D.W. Will, H. Matter, H. Schreuder, K. Ritter, M. Urmann, M. Essrich, A. Bauer, M. Wagner, J. Czech, et al., Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structureeactivity relationship and X-ray crystallography, J. Med. Chem. 48 (2005) 4511-4525.
40. A.R. Voth, P.S. Ho, The role of halogen bonding in inhibitor recognition binding by protein kinases, Curr. Top. Med. Chem. 7 (2007) 1336-1348.
41. X. Liu, M. Tu, R.S. Kelly, C. Chen, B.J. Smith, Development of a computational approach to predict blood-brain barrier permeability, Drug Metab. Dispos. 32 (2004) 132-139.
42. L. Di, E.H. Kerns, K. Fan, O.J. McConnell, G.T. Carter, High throughput artificial membrane permeability assay for blood-brain barrier, Euro J. Med. Chem. 38 (2003) 223-232.
43. L. Di, E.H. Kerns, I.F. Bezar, S.L. Petusky, Y.P. Huang, Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB, J. Pharm. Sci. 98 (2009) 1980-1991.
44. A.M. ter Laak, R.S. Tsai, G.M. Donne-Op den Kelder, P.-A. Carrupt, B. Testa, H. Timmerman, Lipophilicity and hydrogen-bonding capacity of H1-Histaminic agents in relation to their central sedative side effects, Euro. J. Pharm. Sci. 2 (1994) 373-384.
45. J.E.A. Corner, High-throughput measurement of log D and pKa, in: H. van de Waterbeemd, H. Lenneras, P. Artursson (Eds.), Drug Bioavailability, Wiley, Weinheim, Germany, 2004.
46. R.S. Obach, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: examination of in vitro half-life approach and nonspecific binding to microsomes, Drug Metab. Dispos. 27 (1999) 1350-1359.
47. N. Zhang, S.T. Fountain, H. Bi, D.T. Rossi, Quantification and rapid metabolite identification in drug discovery using API time-of-flight LC/MS, Anal. Chem. 72 (2000) 800-806.
48. L. Di, E.H. Kerns, N. Gao, S.Q. Li, Y.P. Huang, J.L. Bourassa, D.M. Huryn, Experimental design on single-time-Point-high-throughput microsomal stability assay, J. Pharm. Sci. 93 (2004) 1537-1544.
49. G.L. Ellman, D. Gourtney, V. Andres, R.M. Featherstone, A new rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol. 7 (1961) 88-95.